AXNX / Axonics, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-38721 Axonics, Inc. (Exact name of registrant as specified in its chart

As filed with the Securities and Exchange Commission on November 15, 2024.

As filed with the Securities and Exchange Commission on November 15, 2024. Registration No. 333-271663 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-271663 UNDER THE SECURITIES ACT OF 1933 Axonics, Inc. (Exact name of registrant as specified in its charter) Delaware 45-4744083 (State or other jurisd

Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2024 Axonics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38721 45-4744083 (State or other jurisdiction of incorporation) (Commission File Nu

As filed with the Securities and Exchange Commission on November 15, 2024.

As filed with the Securities and Exchange Commission on November 15, 2024. Registration No. 333-270332 Registration No. 333-228170 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-270332 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-228170 UNDER THE SECURITIES ACT OF 1933 Ax

As filed with the Securities and Exchange Commission on November 15, 2024.

As filed with the Securities and Exchange Commission on November 15, 2024. Registration No. 333-270332 Registration No. 333-228170 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-270332 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-228170 UNDER THE SECURITIES ACT OF 1933 Ax

SIXTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION AXONICS, INC.

Exhibit 3.1 SIXTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF AXONICS, INC. 1.The name of the corporation is: Axonics, Inc. (the “Corporation”). 2.The address of the registered office of the Corporation in the State of Delaware is Corporation Service Company, 251 Little Falls Drive, Wilmington, DE, county of New Castle, 19808. The name of the registered agent of the Corporation at such ad

BY-LAWS AXONICS, INC. ARTICLE I

Exhibit 3.2 BY-LAWS OF AXONICS, INC. ARTICLE I STOCKHOLDERS Section 1. ANNUAL MEETING. The annual meeting of the stockholders of Axonics, Inc. (the “Corporation”), for the purpose of electing directors and for the transaction of such other business as may be brought before the meeting, shall be held at the principal office of the Corporation, or at such other place within or without the State of D

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 Axonics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38721 45-4744083 (State or other jurisdiction of incorporation) (Commission File Num

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38721 Axoni

Axonics Reports Third Quarter 2024 Financial Results

Exhibit 99.1 Axonics Reports Third Quarter 2024 Financial Results IRVINE, Calif. – November 7, 2024 – Axonics, Inc. (Nasdaq: AXNX), a medical technology company that develops, manufactures and commercializes innovative and minimally invasive products to treat bladder and bowel dysfunction, today reported financial results for the three months ended September 30, 2024. “Axonics continued to execute

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38721 Axonics, I

Axonics Reports Second Quarter 2024 Financial Results Generated record revenue, gross margin and net income in 2Q24

Exhibit 99.1 Axonics Reports Second Quarter 2024 Financial Results Generated record revenue, gross margin and net income in 2Q24 IRVINE, Calif. – August 1, 2024 – Axonics, Inc. (Nasdaq: AXNX), a medical technology company that develops, manufactures and commercializes innovative and minimally invasive products to treat bladder and bowel dysfunction, today reported financial results for the three m

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2024 Axonics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38721 45-4744083 (State or other jurisdiction of incorporation) (Commission File Numbe

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2024 Axonics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38721 45-4744083 (State or other jurisdiction of incorporation) (Commission File Numbe

Axonics Reports First Quarter 2024 Financial Results

Exhibit 99.1 Axonics Reports First Quarter 2024 Financial Results IRVINE, Calif. – April 30, 2024 – Axonics, Inc. (Nasdaq: AXNX), a medical technology company that develops and commercializes innovative and minimally invasive products to treat bladder and bowel dysfunction, today reported financial results for the three months ended March 31, 2024. “Our commercial team continued to execute at a hi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38721 Axonics,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2024 Axonics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38721 45-4744083 (State or other jurisdiction of incorporation) (Commission File Number

Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2024 Axonics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38721 45-4744083 (State or other jurisdiction of incorporation) (Commission File Numbe

Axonics Stockholders Approve Merger Agreement with Boston Scientific

Exhibit 99.1 Axonics Stockholders Approve Merger Agreement with Boston Scientific IRVINE, Calif – (BUSINESS WIRE) – Axonics, Inc. (Nasdaq: AXNX) announced that its stockholders have voted today to adopt Axonics’ merger agreement with Boston Scientific Corporation (NYSE: BSX). According to preliminary voting results from the special meeting of stockholders held earlier today, a majority of the shar

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy State

Amendment to Executive Employment Agreement, dated November 1, 2023, by and between Alfred Ford Jr. and the Registrant.

Exhibit 10.22 AMENDMENT TO AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amendment to the Amended and Restated Executive Employment Agreement (this “Amendment”) is dated as of November 1, 2023 by and between Axonics, Inc., a Delaware corporation (the “Company”), and Alfred Ford Jr. (“Executive”). WHEREAS, Executive currently serves as Chief Commercial Officer of the Company pursuant to

Incentive-based Compensation Recovery Policy

Exhibit 97 AXONICS, INC. INCENTIVE-BASED COMPENSATION RECOVERY POLICY 1.Policy Purpose. The purpose of this Axonics, Inc. (the “Company”) Incentive-Based Compensation Recovery Policy (this “Policy”) is to enable the Company to recover Erroneously Awarded Compensation in the event that the Company is required to prepare an Accounting Restatement. This Policy is intended to comply with the requireme

Amendment to Executive Employment Agreement, dated November 1, 2023, by and between Rinda Sama and the Registrant.

Exhibit 10.20 AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT This Amendment to the Executive Employment Agreement (this “Amendment”) is dated as of November 1, 2023 by and between Axonics, Inc., a Delaware corporation (the “Company”), and Rinda Sama (“Executive”). WHEREAS, Executive currently serves as Chief Operating Officer of the Company pursuant to an Executive Employment Agreement dated June 5,

List of Subsidiaries.

Exhibit 21.1 List of Subsidiaries of Axonics, Inc. Name of Subsidiary Jurisdiction of Incorporation or Organization Axonics Europe, S.A.S. France Axonics Modulation Technologies, U.K. Limited England and Wales Axonics Modulation Technologies Australia Pty Ltd Australia Axonics Women’s Health Limited England and Wales Bulkamid SARL France Axonics GmbH Germany Contura, Inc. United States

Amendment to Executive Employment Agreement, dated November 1, 2023, by and between John Woock, Ph.D. and the Registrant.

Exhibit 10.21 AMENDMENT TO AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amendment to the Amended and Restated Executive Employment Agreement (this “Amendment”) is dated as of November 1, 2023 by and between Axonics, Inc., a Delaware corporation (the “Company”), and John Woock, Ph.D. (“Executive”). WHEREAS, Executive currently serves as Executive Vice President, Chief Marketing & Strate

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38721 Axonics, Inc.

Cash Bonus Incentive Plan

Exhibit 10.23 AXONICS, INC. SUMMARY OF 2024 SPECIAL CASH BONUS INCENTIVE PLAN On January [XX], 2024, the Board of Directors of Axonics, Inc. (“the Company”), based upon the recommendation of the Compensation Committee of the Board of Directors of the Company, approved a special cash bonus incentive plan (the “Plan”) for the year ending December 31, 2024 for the named executive officers of the Comp

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024 Axonics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38721 45-4744083 (State or other jurisdiction of incorporation) (Commission File Nu

Axonics Reports Fourth Quarter and Fiscal Year 2023 Financial Results

Exhibit 99.1 Axonics Reports Fourth Quarter and Fiscal Year 2023 Financial Results IRVINE, Calif – (BUSINESS WIRE) – Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months and fiscal year ended December 31, 2023. “The continued s

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ D

AXNX / Axonics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv0386-axonicsinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Axonics Inc Title of Class of Securities: Common Stock CUSIP Number: 05465P101 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pur

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box: ☒ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))  ☐ D

Calculation of Filing Fee Table SCHEDULE 14A (Form Type) Axonics, Inc. (Name of Registrant as Specified in its Charter) Table 1: Transaction Valuation

Exhibit 107 Calculation of Filing Fee Table SCHEDULE 14A (Form Type) Axonics, Inc.

Agreement and Plan of Merger, dated as of January 8, 2024, among Boston Scientific Corporation, Sadie Merger Sub, Inc. and Axonics, Inc.

Exhibit 2.1 AGREEMENT AND PLAN OF MERGER among BOSTON SCIENTIFIC CORPORATION, SADIE MERGER SUB, INC. and AXONICS, INC. Dated as of January 8, 2024 TABLE OF CONTENTS Page ARTICLE I THE MERGER SECTION 1.01 The Merger 2 SECTION 1.02 Closing 2 SECTION 1.03 Effective Time 2 SECTION 1.04 Effects of the Merger 2 SECTION 1.05 Certificate of Incorporation and Bylaws of the Surviving Corporation 2 SECTION 1

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 Axonics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38721 45-4744083 (State or other jurisdiction of incorporation) (Commission File Numb

Axonics Reports Preliminary 4Q23 and Fiscal Year 2023 Revenue

Exhibit 99.1 Axonics Reports Preliminary 4Q23 and Fiscal Year 2023 Revenue IRVINE, Calif – (BUSINESS WIRE) – Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported preliminary unaudited revenue for the fourth quarter and fiscal year ended December 31, 2023. “The conti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy State

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 Axonics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38721 45-4744083 (State or other jurisdiction of incorporation) (Commission File Numb

Axonics Announces Definitive Agreement to be Acquired by Boston Scientific

Exhibit 99.2 Axonics Announces Definitive Agreement to be Acquired by Boston Scientific IRVINE, Calif – (BUSINESS WIRE) – Axonics, Inc. (Nasdaq: AXNX) today announced that it has entered into a definitive agreement to be acquired by Boston Scientific Corporation (NYSE: BSX) for $71 in cash per share, representing an equity value of approximately $3.7 billion. Axonics brings a complementary product

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38721 Axoni

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2023 Axonics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38721 45-4744083 (State or other jurisdiction of incorporation) (Commission File Num

Axonics Reports Third Quarter 2023 Financial Results Generated quarterly revenue of $93.1 million, an increase of 32% year over year Fiscal year 2023 revenue guidance increased to $362 million

Exhibit 99.1 Axonics Reports Third Quarter 2023 Financial Results Generated quarterly revenue of $93.1 million, an increase of 32% year over year Fiscal year 2023 revenue guidance increased to $362 million IRVINE, Calif. – October 30, 2023 – Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2023 Axonics, Inc. (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2023 Axonics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38721 45-4744083 (State or other jurisdiction of incorporation) (Commission File Numb

Executive Employment Agreement, dated October 2, 2023, by and between the Company and Raymond W. Cohen.

Exhibit 10.2 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (this “Agreement”) is dated as of October 2, 2023 by and between Axonics, Inc., a Delaware corporation (the “Company”), and Raymond W. Cohen (“Executive”). WHEREAS, Executive currently serves as Chief Executive Officer and a director of the Company pursuant to an Executive Employment Agreement with a term scheduled to

Executive Employment Agreement, dated October 2, 2023, by and between the Company and Kari Keese.

Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (this “Agreement”) is dated as of October 2, 2023 by and between Axonics, Inc., a Delaware corporation (the “Company”), and Kari Keese (“Executive”). WHEREAS, Executive shall serve as Chief Financial Officer of the Company. WHEREAS, the Company and Executive desire to continue Executive’s employment with the Company in

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2023 Axonics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38721 45-4744083 (State or other jurisdiction of incorporation) (Commission File Numb

Axonics Announces CFO Retirement and Appoints Successor

Exhibit 99.1 Axonics Announces CFO Retirement and Appoints Successor IRVINE, Calif. – August 21, 2023 – Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that Dan L. Dearen, president and chief financial officer, is retiring from the company. Kari Keese, vice pr

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38721 Axonics, I

Axonics Reports Second Quarter 2023 Financial Results Generated quarterly revenue of $92.9 million, an increase of 35% year over year Fiscal year 2023 revenue guidance increased to $358 million

Exhibit 99.1 Axonics Reports Second Quarter 2023 Financial Results Generated quarterly revenue of $92.9 million, an increase of 35% year over year Fiscal year 2023 revenue guidance increased to $358 million IRVINE, Calif. – July 27, 2023 – Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel d

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2023 Axonics, Inc. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2023 Axonics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38721 45-4744083 (State or other jurisdiction of incorporation) (Commission File Number

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2023 Axonics, Inc. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2023 Axonics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38721 45-4744083 (State or other jurisdiction of incorporation) (Commission File Number

308,913 Shares Axonics, Inc. Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-271663 P R O S P E C T U S S U P P L E M E N T (to prospectus dated May 4, 2023) 308,913 Shares Axonics, Inc. Common Stock This prospectus supplement relates to the possible resale from time to time of 308,913 shares of our common stock, which are held by, or may be issued to, the selling stockholder identified in this prospectus supplement. We

You’ve Exceeded the SEC’s Traffic Limit

Exhibit 107 Calculation of Filing Fee Table 424(b)(5) (Form Type) Axonics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share(2)(3) Maximum Aggregate Offering Price(2)(3) Fee Rate Amount of Registration Fee Equity Common stock, par val

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2023 Axonics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38721 45-4744083 (State or other jurisdiction of incorporation) (Commission File Number)

As filed with the Securities and Exchange Commission on May 4, 2023.

S-3ASR 1 s-3asrmay2023.htm S-3ASR As filed with the Securities and Exchange Commission on May 4, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Axonics, Inc. (Exact name of registrant as specified in its charter) Delaware 45-4744083 (State or other jurisdiction of incorporation or

Form of Indenture

Exhibit 4.4 AXONICS, INC. Issuer AND as Trustee INDENTURE Dated as of , 20 Debt Securities CROSS-REFERENCE TABLE(1) SECTION OF TRUST INDENTURE ACT OF 1939, AS AMENDED SECTION(S) OF INDENTURE 310(b) 7.8 311(a) 7.13 311(b) 7.13 312(a) 5.2(a) 312(b) 5.2(b) 312(c) 5.2(c) 313(a) 5.4(a) 313(b) 5.4(b) 313(c) 5.4(b) (1) This Cross-Reference Table does not constitute part of the Indenture and shall not hav

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Axonics, Inc. (Exact Name of Registrant as Specific in its Charter) Table I: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, par value $0.0001 per sh

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38721 Axonics,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2023 Axonics, Inc. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2023 Axonics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38721 45-4744083 (State or other jurisdiction of incorporation) (Commission File Number)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Definitive Proxy State

Axonics Reports First Quarter 2023 Financial Results Generated quarterly revenue of $70.7 million, an increase of 46% year over year Fiscal year 2023 revenue guidance increased to $348 million

Exhibit 99.1 Axonics Reports First Quarter 2023 Financial Results Generated quarterly revenue of $70.7 million, an increase of 46% year over year Fiscal year 2023 revenue guidance increased to $348 million IRVINE, Calif. – May 1, 2023 – Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysf

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2023 Axonics, Inc. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2023 Axonics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38721 45-4744083 (State or other jurisdiction of incorporation) (Commission File Number

Third Amendment to Lease, dated April 1, 2023, between The Irvine Company LLC and Axonics, Inc.

Exhibit 10.2 THIRD AMENDMENT TO LEASE I. PARTIES AND DATE. This Third Amendment to Lease (“Amendment”) dated April 1, 2023, by and between THE IRVINE COMPANY LLC, a Delaware limited liability company (“Landlord”), and AXONICS, INC., a Delaware corporation (“Tenant”). II. RECITALS. Landlord and Tenant (formerly known as Axonics Modulation Technologies, Inc., a Delaware corporation) are parties to a

Lease, dated April 1, 2023, between Sand Canyon Business Center I LLC and Axonics, Inc.

Exhibit 10.1 LEASE BETWEEN SAND CANYON BUSINESS CENTER I LLC AND AXONICS, INC. LEASE THIS LEASE is made as of April 1, 2023, by and between SAND CANYON BUSINESS CENTER I LLC, a Delaware limited liability company, hereafter called “Landlord,” and AXONICS, INC., a Delaware corporation, hereafter called “Tenant.” ARTICLE 1. BASIC LEASE PROVISIONS Each reference in this Lease to the “Basic Lease Provi

AXNX / Axonics Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Axonics Inc. Title of Class of Securities: Common Stock CUSIP Number: 05465P101 Date of Event Which Requires Filing of this Statement: February 28, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 1

As filed with the Securities and Exchange Commission on March 7, 2023.

As filed with the Securities and Exchange Commission on March 7, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Axonics, Inc. (Exact name of registrant as specified in its charter) Delaware 45-4744083 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer I

Filing fee table.

EXHIBIT 107 Calculation of Filing Fee Table Form S-8 Axonics, Inc. Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, $0.0001 par value per share Other 2,500,000(2) $56.33(3) $140,825,000(3) $0.00011020 $ 15,519 Total Offering Amounts $ 140,8

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38721 Axonics, Inc.

List of Subsidiaries.

Exhibit 21.1 List of Subsidiaries of Axonics, Inc. Name of Subsidiary Jurisdiction of Incorporation or Organization Axonics Europe, S.A.S. France Axonics Modulation Technologies, U.K. Limited England and Wales Axonics Modulation Technologies Australia Pty Ltd Australia Axonics Women’s Health Limited England and Wales Bulkamid SARL France Axonics GmbH Germany Contura, Inc. United States

Amended and Restated Executive Employment Agreement, dated June

Exhibit 10.17 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (this “Agreement”) is dated as of June 5, 2019 by and between Axonics Modulation Technologies, Inc., a Delaware corporation (the “Company”), and Alfred Ford Jr. (“Executive”). WHEREAS, Executive currently serves as Chief Commercial Officer of the Company pursuant to an Executi

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2023 Axonics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38721 45-4744083 (State or other jurisdiction of incorporation) (Commission File Number

Axonics Reports Fourth Quarter and Fiscal Year 2022 Financial Results Generated record quarterly revenue of $86 million, an increase of 62% y/y Reported fiscal year 2022 revenue of $274 million, an increase of 52% y/y Reiterated fiscal year 2023 reve

Exhibit 99.1 Axonics Reports Fourth Quarter and Fiscal Year 2022 Financial Results Generated record quarterly revenue of $86 million, an increase of 62% y/y Reported fiscal year 2022 revenue of $274 million, an increase of 52% y/y Reiterated fiscal year 2023 revenue guidance of $342 million, an increase of 25% y/y IRVINE, Calif – (BUSINESS WIRE) – Axonics, Inc. (Nasdaq: AXNX), a global medical tec

Amended and Restated Executive Employment Agreement, dated June 6, 2019, by and between John Woock, Ph.D. and the Registrant

Exhibit 10.16 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (this “Agreement”) is dated as of June 6, 2019 by and between Axonics Modulation Technologies, Inc., a Delaware corporation (the “Company”), and John Woock, Ph.D. (“Executive”). WHEREAS, Executive currently serves as Chief Marketing Officer of the Company pursuant to an Execut

AXNX / Axonics Modulation Technologies Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Axonics Inc. Title of Class of Securities: Common Stock CUSIP Number: 05465P101 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 1

Axonics Reports Preliminary Fiscal Year 2022 Revenue and Provides Fiscal Year 2023 Revenue Guidance 4Q22 total company net revenue expected to be $85.6 to $86.0 million, an increase of 61% y/y Fiscal year 2022 total company net revenue expected to be

Exhibit 99.1 Axonics Reports Preliminary Fiscal Year 2022 Revenue and Provides Fiscal Year 2023 Revenue Guidance 4Q22 total company net revenue expected to be $85.6 to $86.0 million, an increase of 61% y/y Fiscal year 2022 total company net revenue expected to be in the range of $273.6 million, an increase of 52% y/y Fiscal year 2023 revenue guidance of $342 million, an increase of 25% y/y IRVINE,

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2023 Axonics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38721 45-4744083 (State or other jurisdiction of incorporation) (Commission File Num

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38721 Axoni

Axonics® Reports Third Quarter 2022 Financial Results Generated record quarterly revenue of $70 million, an increase of 50% year over year Fiscal year 2022 revenue guidance raised to $262 million, an increase of 45% year over year

Exhibit 99.1 Axonics® Reports Third Quarter 2022 Financial Results Generated record quarterly revenue of $70 million, an increase of 50% year over year Fiscal year 2022 revenue guidance raised to $262 million, an increase of 45% year over year IRVINE, Calif. – October 31, 2022 – Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2022 Axonics, Inc. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2022 Axonics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38721 45-4744083 (State or other jurisdiction of incorporation) (Commission File Num

Axonics® Announces Closing of Public Stock Offering and Full Exercise of Underwriter’s Option to Purchase Additional Stock

Exhibit 99.3 Axonics? Announces Closing of Public Stock Offering and Full Exercise of Underwriter?s Option to Purchase Additional Stock IRVINE, Calif. ? August 5, 2022 ? Axonics, Inc. (Nasdaq: AXNX) (?Axonics?), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the closing of its public offe

Underwriting Agreement, dated August 2, 2022, by and between Axonics, Inc. and BofA Securities, Inc.

EX-1.1 2 axnx-080522xex11.htm EX-1.1 Exhibit 1.1 AXONICS, INC. (a Delaware corporation) 1,750,000 Shares of Common Stock UNDERWRITING AGREEMENT Dated: August 2, 2022 AXONICS, INC. (a Delaware corporation) 1,750,000 Shares of Common Stock UNDERWRITING AGREEMENT August 2, 2022 BofA Securities, Inc. One Bryant Park New York, New York 10036 Ladies and Gentlemen: Axonics, Inc., a Delaware corporation (

Axonics® Announces Pricing of Public Offering of Common Stock

Exhibit 99.2 Axonics? Announces Pricing of Public Offering of Common Stock IRVINE, Calif. ? August 2, 2022 ? Axonics, Inc. (Nasdaq: AXNX) (?Axonics?), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that it priced its previously announced underwritten public offering of 1,750,000 shares of

Axonics® Announces Proposed Public Offering of Common Stock

Exhibit 99.1 Axonics? Announces Proposed Public Offering of Common Stock IRVINE, Calif. ? August 2, 2022 ? Axonics, Inc. (Nasdaq: AXNX) (?Axonics?), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that it has commenced a proposed underwritten public offering of 1,750,000 shares of its comm

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2022 Axonics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38721 45-4744083 (State or other jurisdiction of incorporation) (Commission File Numbe

Calculation of Filing Fee Tables (Form Type) Axonics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule(1) Amoun

Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Axonics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule(1) Amount Registered(2) Proposed Maximum Offering Price Per Unit(1) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee

1,750,000 Shares Axonics, Inc. Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-238064 P R O S P E C T U S S U P P L E M E N T (to prospectus dated May 7, 2020) 1,750,000 Shares Axonics, Inc. Common Stock We are offering 1,750,000 shares of our common stock, par value $0.0001 per share. Our common stock trades on the Nasdaq Global Select Market, or Nasdaq, under the trading symbol ?AXNX.? On August 1, 2022, the last report

SUBJECT TO COMPLETION, DATED AUGUST 2, 2022

424B5 1 axnx-080222x424b5document.htm 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-238064 The information in this prospectus supplement is not complete and may be changed. This prospectus supplement is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted. SUBJECT TO COMPLETION, DATED AUG

SUBJECT TO COMPLETION, DATED AUGUST 2, 2022

Filed Pursuant to Rule 424(b)(5) Registration No. 333-238064 The information in this prospectus supplement is not complete and may be changed. This prospectus supplement is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted. SUBJECT TO COMPLETION, DATED AUGUST 2, 2022 P R O S P E C T U S S U P P L E

Axonics® Reports Second Quarter 2022 Financial Results Generated record quarterly revenue of $69 million in 2Q22, an increase of 50% compared to 2Q21 Fiscal year 2022 revenue guidance increased to $253 million, an increase of 40% compared to fiscal y

Exhibit 99.1 Axonics? Reports Second Quarter 2022 Financial Results Generated record quarterly revenue of $69 million in 2Q22, an increase of 50% compared to 2Q21 Fiscal year 2022 revenue guidance increased to $253 million, an increase of 40% compared to fiscal year 2021 IRVINE, Calif. ? August 1, 2022 ? Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and comme

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2022 Axonics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38721 45-4744083 (State or other jurisdiction of incorporation) (Commission File Numbe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38721 Axonics, I

JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1)

Exhibit 1 Exhibit 1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements.

AXNX / Axonics Modulation Technologies Inc / Cooperatieve Gilde Healthcare IV U.A. - SC 13G/A Passive Investment

SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* AXONICS, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 05465P101 (CUSIP number) June 6, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w

Certificate of Amendment to Amended and Restated Bylaws, dated May 31, 2022.

Exhibit 3.2 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED BYLAWS OF AXONICS, INC. a Delaware corporation The undersigned hereby certifies that he is the duly elected, qualified, and acting Secretary of Axonics, Inc., a Delaware corporation (the ?Corporation?), and that the Amended and Restated Bylaws of the Corporation have been amended to amend and restate Section 7.6 thereof as set forth belo

First Amendment to the Axonics, Inc. 2018 Omnibus Incentive Plan.

Exhibit 10.1 FIRST AMENDMENT TO THE AXONICS, INC. 2018 OMNIBUS INCENTIVE PLAN WHEREAS, Axonics, Inc., a Delaware corporation (?Company?), established and sponsors the Axonics, Inc. 2018 Omnibus Incentive Plan (the ?Plan?)? WHEREAS, the Company and its stockholders previously approved and adopted the Plan, effective on October 18, 2018; WHEREAS, the Plan reserved for issuance an aggregate of 4,500,

Certificate of Amendment to Amended and Restated Certificate of Incorporation, dated May 31, 2022.

Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF AXONICS, INC. a Delaware corporation Axonics, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the ?Corporation?), certifies that: FIRST: The Board of Directors of the Corporation duly adopted resolutions proposing and declaring advisab

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2022 Axonics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38721 45-4744083 (State or other jurisdiction of incorporation) (Commission File Number)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14 Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1)

DEFR14A 1 axnx-2022xdefr14a.htm DEFR14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14 Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38721 Axonics,

Axonics® Reports First Quarter 2022 Financial Results

Exhibit 99.1 Axonics? Reports First Quarter 2022 Financial Results IRVINE, Calif. ? May 5, 2022 ? Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months ended March 31, 2022. ?We are pleased with this quarter?s revenue result con

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 Axonics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38721 45-4744083 (State or other jurisdiction of incorporation) (Commission File Number)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant o Check the appropriate box: ? Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy State

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2022 Axonics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38721 45-4744083 (State or other jurisdiction of incorporation) (Commission File Number

Axonics® Receives FDA Approval for Recharge-Free Sacral Neuromodulation System Axonics sets recharge-free neuromodulation benchmark with FDA labeling for 15+ years of functional life at typical stimulation parameters and 20+ years at lower energy set

Exhibit 99.1 Axonics® Receives FDA Approval for Recharge-Free Sacral Neuromodulation System Axonics sets recharge-free neuromodulation benchmark with FDA labeling for 15+ years of functional life at typical stimulation parameters and 20+ years at lower energy settings IRVINE, Calif – March 7, 2022 – Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercial

List of Subsidiaries.

Exhibit 21.1 List of Subsidiaries of Axonics, Inc. Name of Subsidiary Jurisdiction of Incorporation or Organization Axonics Europe, S.A.S. France Axonics Modulation Technologies, U.K. Limited England and Wales Axonics Modulation Technologies Australia Pty Ltd Australia Axonics Women?s Health Limited England and Wales Bulkamid SARL France Axonics GmbH Germany Contura, Inc. United States

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38721 Axonics, Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2022 Axonics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38721 45-4744083 (State or other jurisdiction of incorporation) (Commission File Nu

Axonics® Reports Fourth Quarter and Fiscal Year 2021 Financial Results Total revenue of $53.1 million in 4Q21, an increase of 53% year over year Fiscal year 2022 revenue outlook of $234 million, an increase of 30% year over year

Exhibit 99.1 Axonics? Reports Fourth Quarter and Fiscal Year 2021 Financial Results Total revenue of $53.1 million in 4Q21, an increase of 53% year over year Fiscal year 2022 revenue outlook of $234 million, an increase of 30% year over year IRVINE, Calif ? February 24, 2022 ? Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products fo

AXNX / Axonics Modulation Technologies Inc / CREDIT SUISSE AG/ - NONE Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 01)* Axonics, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 05465P101 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu

In accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998), this Statement is being filed by Credit Suisse AG (the "Bank"), a Swiss bank, on behalf of its subsidiaries to the extent that they conduct business as the

In accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998), this Statement is being filed by Credit Suisse AG (the "Bank"), a Swiss bank, on behalf of its subsidiaries to the extent that they conduct business as the Swiss Universal Bank, Asia Pacific, International Wealth Management, Global Markets, Investment Banking & Capital Markets and the Strategic Resolutio

AXNX / Axonics Modulation Technologies Inc / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Axonics Inc. Title of Class of Securities: Common Stock CUSIP Number: 05465P101 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ??Rule 13d-1(b) ??Rule 13d-1

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2022 Axonics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38721 45-4744083 (State or other jurisdiction of incorporation) (Commission File Numb

Axonics® Reports Preliminary Fourth Quarter and Fiscal Year 2021 Revenue Quarterly revenue exceeds $50 million for the first time

Exhibit 99.1 Axonics? Reports Preliminary Fourth Quarter and Fiscal Year 2021 Revenue Quarterly revenue exceeds $50 million for the first time IRVINE, Calif ? January 6, 2022 ? Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported preliminary unaudited net revenue fo

Asset Test – 1.1% Investment Test – 9.5% Income Test – 9.8%

VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Attn: Kristin Lochhead Brian Cascio Re: Axonics, Inc. Form 10-K for the Fiscal Year Ended December 31, 2020 Filed March 1, 2021 Form 10-Q for the Quarterly Period Ended June 30, 2021 Filed August 5, 2021 File No. 001-38721 Ladies and Gentlemen, Axonics, Inc., a Delaware corp

Axonics® Reports Third Quarter 2021 Financial Results

Exhibit 99.1 Axonics? Reports Third Quarter 2021 Financial Results IRVINE, Calif ? November 4, 2021 ? Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the third quarter ended September 30, 2021. ?We are pleased with this quarter?s revenue r

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38721 Axoni

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2021 Axonics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38721 45-4744083 (State or other jurisdiction of incorporation) (Commission File Num

Axonics® Reports Second Quarter 2021 Financial Results Total revenue of $45.9 million in 2Q21, including record SNM revenue of $40.2 million Bulkamid® revenue of $5.7 million in first full quarter since acquisition Fiscal year 2021 revenue guidance i

Exhibit 99.1 Axonics? Reports Second Quarter 2021 Financial Results Total revenue of $45.9 million in 2Q21, including record SNM revenue of $40.2 million Bulkamid? revenue of $5.7 million in first full quarter since acquisition Fiscal year 2021 revenue guidance increased to a range of $186 million to $188 million IRVINE, Calif ? August 5, 2021 ? Axonics, Inc. (Nasdaq: AXNX), a global medical techn

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38721 Axonics, I

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 Axonics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38721 45-4744083 (State or other jurisdiction of incorporation) (Commission File Numbe

Axonics® Announces Appointment of Dr. Esteban López to its Board of Directors

Exhibit 99.1 Axonics? Announces Appointment of Dr. Esteban L?pez to its Board of Directors IRVINE, Calif ? July 15, 2021 ? Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the appointment of Esteban L?pez, M.D., MBA, to its board of directors, effective immedia

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2021 Axonics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38721 45-4744083 (State or other jurisdiction of incorporation) (Commission File Number

Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2021 Axonics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38721 45-4744083 (State or other jurisdiction of incorporation) (Commission File Number

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2021 Axonics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38721 45-4744083 (State or other jurisdiction of incorporation) (Commission File Number

Underwriting Agreement, dated May 11, 2021, by and among Axonics, Inc. and BofA Securities, Inc., Piper Sandler & Co. and SVB Leerink LLC

Exhibit 1.1 AXONICS, INC. (a Delaware corporation) 3,500,000 Shares of Common Stock UNDERWRITING AGREEMENT Dated: May 11, 2021 AXONICS, INC. (a Delaware corporation) 3,500,000 Shares of Common Stock UNDERWRITING AGREEMENT May 11, 2021 BofA Securities, Inc. Piper Sandler & Co. SVB Leerink LLC as Representatives of the several Underwriters c/o BofA Securities, Inc. One Bryant Park New York, New York

Axonics® Announces Upsize and Pricing of Public Offering of Common Stock

Exhibit 99.2 Axonics? Announces Upsize and Pricing of Public Offering of Common Stock IRVINE, Calif. ? May 11, 2021 ? Axonics, Inc. (Nasdaq: AXNX) (?Axonics?), a global medical technology company that has developed and is commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the pricing of its public offering of 3,500,000 shares of its common stock at a

Axonics® Announces Closing of Public Stock Offering and Full Exercise of Underwriters’ Option to Purchase Additional Stock

Exhibit 99.3 Axonics? Announces Closing of Public Stock Offering and Full Exercise of Underwriters? Option to Purchase Additional Stock IRVINE, Calif. ? May 14, 2021 ? Axonics, Inc. (Nasdaq: AXNX), (?Axonics?), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the closing of its public offer

Axonics® Announces Proposed Public Offering of Common Stock

Exhibit 99.1 Axonics? Announces Proposed Public Offering of Common Stock IRVINE, Calif. ? May 11, 2021 ? Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that it has commenced a proposed public offering of $150,000,000 in shares of its common stock. Axonics exp

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2021 Axonics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38721 45-4744083 (State or other jurisdiction of incorporation) (Commission File Number)

CALCULATION OF REGISTRATION FEE Title of each class of securities to be registered Amount to be registered(1) Maximum offering price per share Maximum aggregate offering price Amount of registration fee(2) Common stock, par value $0.0001 per share 4,

Filed Pursuant to Rule 424(b)(5) Registration No. 333-238064 CALCULATION OF REGISTRATION FEE Title of each class of securities to be registered Amount to be registered(1) Maximum offering price per share Maximum aggregate offering price Amount of registration fee(2) Common stock, par value $0.0001 per share 4,025,000 shares $50.00 $201,250,000 $21,956.38 (1) Includes 525,000 shares of common stock

SUBJECT TO COMPLETION, DATED MAY 11, 2021

Filed Pursuant to Rule 424(b)(5) Registration No. 333-238064 The information in this prospectus supplement is not complete and may be changed. This prospectus supplement is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted. SUBJECT TO COMPLETION, DATED MAY 11, 2021 P R O S P E C T U S S U P P L E M

Exclusive Manufacturing and Supply Agreement, dated February 25, 2021, by and between Contura International A/S and Contura Limited.

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38721 Axonics,

Loan and Security Agreement, dated as of February 25, 2021, by and among Silicon Valley Bank and Axonics, Inc.

LOAN AND SECURITY AGREEMENT This LOAN AND SECURITY AGREEMENT (this ?Agreement?) dated as of February 25, 2021 (the ?Effective Date?) by and among (a) SILICON VALLEY BANK, a California corporation (?SVB?), in its capacity as administrative agent and collateral agent (?Agent?), (b) SVB, as a lender, (c) SVB INNOVATION CREDIT FUND VIII, L.

Agreement, dated February 25, 2021, by and among Axonics, Inc., Axonics Modulation Technologies, U.K. Limited and Contura Holdings.

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2021 Axonics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38721 45-4744083 (State or other jurisdiction of incorporation) (Commission File Number)

Axonics® Reports First Quarter 2021 Financial Results

Exhibit 99.1 Axonics? Reports First Quarter 2021 Financial Results IRVINE, Calif ? May 6, 2021 ? Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the first quarter ended March 31, 2021. ?This quarter?s revenue result reflects growing demand

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2021 Axonics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38721 45-4744083 (State or other jurisdiction of incorporation) (Commission File Numbe

CALCULATION OF REGISTRATION FEE Title of each class of securities to be registered Amount to be registered(1)(3) Maximum offering price per share(2)(4) Maximum aggregate offering price(2)(4) Amount of registration fee(2)(4) Common stock, par value $0

Filed Pursuant to Rule 424(b)(5) Registration No. 333-238064 CALCULATION OF REGISTRATION FEE Title of each class of securities to be registered Amount to be registered(1)(3) Maximum offering price per share(2)(4) Maximum aggregate offering price(2)(4) Amount of registration fee(2)(4) Common stock, par value $0.0001 per share 1,096,583 shares $62.24 $68,251,326 $7,447 (1) We are hereby registering

Schedule 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Axonics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities)

Amendment No. 2 to Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Axonics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 05465P101 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropria

Certificate of Amendment of Amended and Restated Certificate of Incorporation of Registrant filed April 1, 2021.

Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF AXONICS MODULATION TECHNOLOGIES, INC. a Delaware corporation Axonics Modulation Technologies, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the ?Corporation?), certifies that: 1.This Certificate of Amendment of its Amended and Restat

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2021 Axonics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38721 45-4744083 (State or other jurisdiction of incorporation) (Commission File Numbe

Axonics® Announces Strategic Alliance for the Manufacture of New Non-Rechargeable Implantable Sacral Neuromodulation Device

Exhibit 99.2 Axonics? Announces Strategic Alliance for the Manufacture of New Non-Rechargeable Implantable Sacral Neuromodulation Device IRVINE, Calif. ? March 2, 2021 ? Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Completion of Acquisition or Disposition of Assets, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2021 Axonics Modulation Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38721 45-4744083 (State or other jurisdiction of incorporat

Axonics® Expands into Stress Urinary Incontinence with the Acquisition of Bulkamid®

EX-99.1 3 axnx-030221xex991.htm EX-99.1 Exhibit 99.1 Axonics® Expands into Stress Urinary Incontinence with the Acquisition of Bulkamid® Combination creates a global leader for incontinence solutions Acquisition of Bulkamid is expected to be immediately accretive to Axonics IRVINE, Calif. – February 25, 2021 – Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that

CALCULATION OF REGISTRATION FEE Title of each class of securities to be registered Amount to be registered Maximum offering price per share Maximum aggregate offering price Amount of registration fee(1) Common stock, par value $0.0001 per share 65,59

Filed Pursuant to Rule 424(b)(5) Registration No. 333-238064 CALCULATION OF REGISTRATION FEE Title of each class of securities to be registered Amount to be registered Maximum offering price per share Maximum aggregate offering price Amount of registration fee(1) Common stock, par value $0.0001 per share 65,594 shares $50.28 $3,298,066.32 $359.82 (1) Calculated in accordance with Rule 457(r) under

List of Subsidiaries.

EX-21.1 3 a12312020-exhibit211.htm EX-21.1 Exhibit 21.1 List of Subsidiaries of Axonics Modulation Technologies, Inc. Name of Subsidiary Jurisdiction of Incorporation or Organization Axonics Europe, S.A.S. France Axonics Modulation Technologies, U.K. Limited England and Wales Axonics Modulation Technologies Australia Pty Ltd Australia

Description of Securities.

EX-4.4 2 a12312020-exhibit44.htm EX-4.4 Exhibit 4.4 Description of the Registrant's Securities Registered Under Section 12 of the Securities Exchange Act of 1934 The following is a description of the capital stock of Axonics Modulation Technologies, Inc. Our common stock, par value $0.0001 per share, is registered under Section 12 of the Securities Exchange Act of 1934, as amended, while our prefe

Annual Report - 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38721 Axonics Modula

Axonics® Reports Fourth Quarter and Fiscal Year 2020 Results

EX-99.1 2 axnx-123120xex991.htm EX-99.1 Exhibit 99.1 Axonics® Reports Fourth Quarter and Fiscal Year 2020 Results IRVINE, Calif – February 25, 2021 – Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today reported res

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2021 Axonics Modulation Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38721 45-4744083 (State or other jurisdiction of incorporat

In accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998), this Statement is being filed by Credit Suisse AG (the "Bank"), a Swiss bank, on behalf of its subsidiaries to the extent that they conduct business as the

In accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998), this Statement is being filed by Credit Suisse AG (the "Bank"), a Swiss bank, on behalf of its subsidiaries to the extent that they conduct business as the Swiss Universal Bank, Asia Pacific, International Wealth Management, Global Markets, Investment Banking & Capital Markets and the Strategic Resolutio

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1) * Axoni

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* Axonics Modulation Technologies, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Tit

Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* Axonics Modulation Technologies, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 05465P101 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the a

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* AXONICS MODULATION TECHNOLOGIES, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Se

SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* AXONICS MODULATION TECHNOLOGIES, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 05465P101 (CUSIP number) M.O.J.M. Perret Cooperatieve Gilde Healthcare IV U.A. Newtonlaan 91 3584 BP Utrecht The Netherlands (Name,

JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1)

EX-99.1 Exhibit 1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersig

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 2) AXONICS MODULATION TECHNOLOGIES, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 2) AXONICS MODULATION TECHNOLOGIES, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 05465P101 (CUSIP Number) DECEMBER 31, 2020 (Date of event which requires filing of this statement) Check the appropriate box to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)*

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) AXONICS MODULATION TECHNOLOGIES, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Sec

SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) AXONICS MODULATION TECHNOLOGIES, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 05465P101 (CUSIP Number) Patrick G. Enright Managing Member Longitude Capital Partners III, LLC 2740 Sand Hill Road, 2nd Floor Menlo

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2021 Axonics Modulation Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38721 45-4744083 (State or other jurisdiction of incorporati

Axonics® Reports Preliminary Fourth Quarter and Fiscal Year 2020 Revenue

Exhibit 99.1 Axonics® Reports Preliminary Fourth Quarter and Fiscal Year 2020 Revenue IRVINE, Calif – January 25, 2021 – Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today reported preliminary unaudited net revenu

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2020 Axonics Modulation Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38721 45-4744083 (State or other jurisdiction of incorporat

Axonics® Announces Appointment of David M. Demski to Board of Directors

EX-99.1 2 axnx-121420xex991.htm EX-99.1 Exhibit 99.1 Axonics® Announces Appointment of David M. Demski to Board of Directors IRVINE, Calif – December 14, 2020 – Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today a

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38721 Axoni

Axonics® Reports Third Quarter 2020 Results Axonics generated net revenue of $35.2 million in the third quarter ended September 30, 2020 Over 5,500 patients have been implanted with the Axonics r-SNM System since U.S. commercial launch

Exhibit 99.1 Axonics® Reports Third Quarter 2020 Results Axonics generated net revenue of $35.2 million in the third quarter ended September 30, 2020 Over 5,500 patients have been implanted with the Axonics r-SNM System since U.S. commercial launch IRVINE, CA – November 4, 2020 – Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercial

Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2020 Axonics Modulation Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38721 45-4744083 (State or other jurisdiction of incorporati

AXNX / Axonics Modulation Technologies, Inc. / Longitude Capital Partners III, LLC - SC 13D/A Activist Investment

SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) AXONICS MODULATION TECHNOLOGIES, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 05465P101 (CUSIP Number) Patrick G. Enright Managing Member Longitude Capital Partners III, LLC 2740 Sand Hill Road, 2nd Floor Menlo

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38721 Axonics Mod

Axonics® Reports Second Quarter 2020 Results

EX-99.1 2 axnx-063020xex991.htm EXHIBIT 99.1 Exhibit 99.1 Axonics® Reports Second Quarter 2020 Results IRVINE, CA – August 6, 2020 – Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today reported financial results fo

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2020 Axonics Modulation Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38721 45-4744083 (State or other jurisdiction of incorporation

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2020 Axonics Modulation Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38721 45-4744083 (State or other jurisdiction of incorporation)

Axonics® Reports Preliminary Second Quarter 2020 Revenue

Exhibit 99.1 Axonics® Reports Preliminary Second Quarter 2020 Revenue IRVINE, CA – July 13, 2020 – Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today reported preliminary unaudited second quarter 2020 revenue and

Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2020 Axonics Modulation Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38721 45-4744083 (State or other jurisdiction of incorporation)

- DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy State

AXNX / Axonics Modulation Technologies, Inc. / Andera Partners Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.

Axonics® Announces Pricing of Public Offering of Common Stock

EX-99.2 5 axnx-050720xex992.htm EXHIBIT 99.2 Exhibit 99.2 Axonics® Announces Pricing of Public Offering of Common Stock IRVINE, Calif – May 7, 2020 – Axonics Modulation Technologies, Inc. (NASDAQ: AXNX) (“Axonics”), a medical technology company that has developed and is commercializing novel implantable rechargeable sacral neuromodulation (“SNM”) devices for the treatment of bladder and bowel dysf

Axonics® Announces Proposed Public Offering of Common Stock

Exhibit 99.1 Axonics® Announces Proposed Public Offering of Common Stock IRVINE, Calif – May 7, 2020 – Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced that it has commenced a proposed public offerin

Axonics® Announces Closing of Public Stock Offering and Full Exercise of Underwriters’ Option to Purchase Additional Stock

Exhibit 99.3 Axonics® Announces Closing of Public Stock Offering and Full Exercise of Underwriters’ Option to Purchase Additional Stock IRVINE, Calif – May 12, 2020 – Axonics Modulation Technologies, Inc. (NASDAQ: AXNX) (“Axonics”), a medical technology company that has developed and is commercializing novel implantable rechargeable sacral neuromodulation (“SNM”) devices for the treatment of bladd

Underwriting Agreement, dated May 7, 2020, by and among Axonics Modulation Technologies, Inc. and BofA Securities, Inc., Morgan Stanley & Co. LLC and Wells Fargo Securities, LLC

Exhibit 1.1 AXONICS MODULATION TECHNOLOGIES, INC. (a Delaware corporation) 4,000,000 Shares of Common Stock UNDERWRITING AGREEMENT Dated: May 7, 2020 AXONICS MODULATION TECHNOLOGIES, INC. (a Delaware corporation) 4,000,000 Shares of Common Stock UNDERWRITING AGREEMENT May 7, 2020 BofA Securities, Inc. Morgan Stanley & Co. LLC Wells Fargo Securities LLC as Representatives of the several Underwriter

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2020 Axonics Modulation Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38721 45-4744083 (State or other jurisdiction of incorporation) (

CALCULATION OF REGISTRATION FEE Title of each class of securities to be registered Amount to be registered(1) Maximum offering price per share Maximum aggregate offering price Amount of registration fee(2) Common stock, par value $0.0001 per share 4,

Filed Pursuant to Rule 424(b)(5) Registration No. 333-238064 CALCULATION OF REGISTRATION FEE Title of each class of securities to be registered Amount to be registered(1) Maximum offering price per share Maximum aggregate offering price Amount of registration fee(2) Common stock, par value $0.0001 per share 4,600,000 shares $32.50 $149,500,000.00 $19,405.10 (1) Includes 600,000 shares of common st

Form of Indenture

Exhibit 4.4 AXONICS MODULATION TECHNOLOGIES, INC. Issuer AND as Trustee INDENTURE Dated as of , 20 Debt Securities CROSS-REFERENCE TABLE(1) SECTION OF TRUST INDENTURE ACT OF 1939, AS AMENDED SECTION(S) OF INDENTURE 310(b) 7.8 311(a) 7.13 311(b) 7.13 312(a) 5.2(a) 312(b) 5.2(b) 312(c) 5.2(c) 313(a) 5.4(a) 313(b) 5.4(b) 313(c) 5.4(b) (1) This Cross-Reference Table does not constitute part of the Ind

- S-3ASR

As filed with the Securities and Exchange Commission on May 7, 2020. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Axonics Modulation Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 45-4744083 (State or other jurisdiction of incorporation or organizati

SUBJECT TO COMPLETION, DATED MAY 7, 2020

Filed Pursuant to Rule 424(b)(5) Registration No. 333-238064 The information in this prospectus supplement is not complete and may be changed. This prospectus supplement is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted. SUBJECT TO COMPLETION, DATED MAY 7, 2020 P R O S P E C T U S S U P P L E M E

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38721 Axonics M

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2020 Axonics Modulation Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38721 45-4744083 (State or other jurisdiction of incorporation) (

Axonics® Reports First Quarter 2020 Results

Exhibit 99.1 Axonics® Reports First Quarter 2020 Results IRVINE, CA – May 5, 2020 – Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today reported financial results for the first quarter 2020 and provided an update

Axonics® Names Michael H. Carrel as Chairman of its Board of Directors

Exhibit 99.1 Axonics® Names Michael H. Carrel as Chairman of its Board of Directors IRVINE, Calif – April 29, 2020 – Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, announced today the appointment of Michael H. Car

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2020 Axonics Modulation Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38721 45-4744083 (State or other jurisdiction of incorporation

Schedule 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Definitive Proxy State

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 16, 2020 Axonics Modulation Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38721 45-4744083 (State or other jurisdiction of incorporation

AXNX / Axonics Modulation Technologies, Inc. / Flynn James E Passive Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No.

December 31, 2019

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38721 Axonics Modula

List of Subsidiaries.

Exhibit 21.1 List of Subsidiaries of Axonics Modulation Technologies, Inc. Name of Subsidiary Jurisdiction of Incorporation or Organization Axonics Europe, S.A.S. France Axonics Modulation Technologies, U.K. Limited England and Wales Axonics Modulation Technologies Australia Pty Ltd Australia

Axonics® Announces Fourth Quarter and Fiscal 2019 Financial Results

Exhibit 99.1 Axonics® Announces Fourth Quarter and Fiscal 2019 Financial Results IRVINE, CA – March 4, 2020 – Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, reported today financial results for the fourth quarter

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2020 Axonics Modulation Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38721 45-4744083 (State or other jurisdiction of incorporation)

Description of Securities.

Exhibit 4.4 Description of the Registrant's Securities Registered Under Section 12 of the Securities Exchange Act of 1934 The following is a description of the capital stock of Axonics Modulation Technologies, Inc. Our common stock, par value $0.0001 per share, is registered under Section 12 of the Securities Exchange Act of 1934, as amended, while our preferred stock, par value $0.0001 per share,

AXNX / Axonics Modulation Technologies, Inc. / RTW INVESTMENTS, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

Joint Filing Statement Pursuant to Rule 13d-1(k)(1)

Exhibit 1 Joint Filing Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to the joint filing of Schedule 13G Amendment No.

AXNX / Axonics Modulation Technologies, Inc. / Advent Life Sciences LLP - FORM SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Axonics Modulation Technologies, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 05465P101 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box t

AXNX / Axonics Modulation Technologies, Inc. / Alfred E. Mann Foundation For Scientific Research - AMENDMENT NO. 1 TO SCHEDULE 13G Passive Investment

Amendment No. 1 to Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Axonics Modulation Technologies, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 05465P101 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statem

AXNX / Axonics Modulation Technologies, Inc. / Andera Partners Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.

AXNX / Axonics Modulation Technologies, Inc. / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) AXONICS MODULATION TECHNOLOGIES, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 05465P101 (CUSIP Number) DECEMBER 31, 2019 (Date of event which requires filing of this statement) Check the appropriate box to

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2020 Axonics Modulation Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38721 45-4744083 (State or other jurisdiction of incorporatio

Axonics® Announces Preliminary Fourth Quarter and Full Year 2019 Revenue

EX-99.1 2 axnx-01092020xex991.htm EXHIBIT 99.1 Exhibit 99.1 Axonics® Announces Preliminary Fourth Quarter and Full Year 2019 Revenue IRVINE, Calif. – January 9, 2020 – Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable rechargeable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowe

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2019 Axonics Modulation Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38721 45-4744083 (State or other jurisdiction of incorporat

Second Amendment to Loan and Security Agreement, dated as of December 30, 2019, by and between Axonics Modulation Technologies, Inc. and Silicon Valley Bank.

Exhibit 1.1 SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS SECOND AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into this 30th day of December, 2019, by and between SILICON VALLEY BANK, a California corporation (“Bank”) and AXONICS MODULATION TECHNOLOGIES, INC., a Delaware corporation (“Borrower”). RECITALS A.Bank and Borrower have entered into that certain Loan and

Axonics® Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares

Exhibit 99.1 Axonics® Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares IRVINE, Calif – December 12, 2019 – Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), (“Axonics”), a medical technology company that has developed and is commercializing novel implantable rechargeable sacral neuromodulation (“SNM”) devices for the treatment of bladder and bowel dysfunction, toda

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2019 Axonics Modulation Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38721 45-4744083 (State or other jurisdiction of incorporat

AXNX / Axonics Modulation Technologies, Inc. / Cooperatieve Gilde Healthcare Iv U.a. - SC 13G Passive Investment

SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* AXONICS MODULATION TECHNOLOGIES, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 05465P101 (CUSIP number) M.O.J.M. Perret Cooperatieve Gilde Healthcare IV U.A. Newtonlaan 91 3584 BP Utrecht The Netherlands (Name, Ad

JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1)

EX-99.1 Exhibit 1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersig

AXNX / Axonics Modulation Technologies, Inc. / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 AXONICS MODULATION TECHNOLOGIES, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 05465P101 (CUSIP Number) NOVEMBER 27, 2019 (Date of event which requires filing of this statement) Check the appropriate box to designate the rul

AXNX / Axonics Modulation Technologies, Inc. / Andera Partners Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.

AXNX / Axonics Modulation Technologies, Inc. / Cooperatieve Gilde Healthcare Iv U.a. - SC 13D/A Activist Investment

SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 1)* AXONICS MODULATION TECHNOLOGIES, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 05465P101 (CUSIP number) M.O.J

Axonics® Announces Closing of $110 Million Public Offering of Common Stock

Exhibit 99.1 Axonics® Announces Closing of $110 Million Public Offering of Common Stock IRVINE, Calif – November 22, 2019 – Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), (“Axonics”), a medical technology company that has developed and is commercializing novel implantable rechargeable sacral neuromodulation (“SNM”) devices for the treatment of bladder and bowel dysfunction, today announced

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2019 Axonics Modulation Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38721 45-4744083 (State or other jurisdiction of incorporat

5,000,000 Shares Axonics Modulation Technologies, Inc. Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-234546 P R O S P E C T U S S U P P L E M E N T (to prospectus dated November 18, 2019) 5,000,000 Shares Axonics Modulation Technologies, Inc. Common Stock We are selling 4,595,000 shares of our common stock, and the selling stockholders identified in this prospectus supplement are selling 405,000 shares of our common stock. We will not receive

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2019 Axonics Modulation Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38721 45-4744083 (State or other jurisdiction of incorporat

Form of Lock-Up Agreement for certain directors, officers, and other stockholders of the Issuer (included as Exhibit A to the form of Underwriting Agreement filed as Exhibit 1.1 to the Current Report on Form 8-K filed by Issuer on November 19, 2019 and incorporated here by reference).

Exhibit 1.1 AXONICS MODULATION TECHNOLOGIES, INC. (a Delaware corporation) 5,000,000 Shares of Common Stock UNDERWRITING AGREEMENT Dated: November 19, 2019 1 AXONICS MODULATION TECHNOLOGIES, INC. (a Delaware corporation) 5,000,000 Shares of Common Stock UNDERWRITING AGREEMENT November 19, 2019 BofA Securities, Inc. Barclays Capital Inc. as Representatives of the several Underwriters c/o BofA Secur

Axonics® Announces Proposed Public Offering of Common Stock

Exhibit 99.1 Axonics® Announces Proposed Public Offering of Common Stock IRVINE, Calif – November 19, 2019 – Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable rechargeable sacral neuromodulation (“SNM”) devices for the treatment of bladder and bowel dysfunction, today announced that it has commenced a prop

Axonics® Announces Pricing of Public Offering of Common Stock

Exhibit 99.2 Axonics® Announces Pricing of Public Offering of Common Stock IRVINE, Calif – November 19, 2019 – Axonics Modulation Technologies, Inc. (NASDAQ: AXNX) (“Axonics”), a medical technology company that has developed and is commercializing novel implantable rechargeable sacral neuromodulation (“SNM”) devices for the treatment of bladder and bowel dysfunction, today announced the pricing of

SUBJECT TO COMPLETION, DATED NOVEMBER 19, 2019

Filed Pursuant to Rule 424(b)(5) Registration No. 333-234546 The information in this prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This prospectus supplement is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any

AXNX / Axonics Modulation Technologies, Inc. CORRESP - -

Axonics Modulation Technologies, Inc. 26 Technology Drive Irvine, CA 92618 November 15, 2019 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Chris Edwards Re: Axonics Modulation Technologies, Inc. Registration Statement on Form S-3 Filed on November 6, 2019 File No. 333-234546 Request for Acceleration Acceleration Re

Axonics® Announces Third Quarter 2019 Financial Results and Operational Update

Exhibit 99.1 Axonics® Announces Third Quarter 2019 Financial Results and Operational Update IRVINE, CA – November 14, 2019 – Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, reported today financial results for the

AXNX / Axonics Modulation Technologies, Inc. 10-Q - Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38721 Axoni

Axonics® Announces U.S. Food & Drug Administration Approval for its Sacral Neuromodulation System for Urinary Clinical Indications

EX-99.1 2 axnx-111419xex991.htm EXHIBIT 99.1 Exhibit 99.1 Axonics® Announces U.S. Food & Drug Administration Approval for its Sacral Neuromodulation System for Urinary Clinical Indications Irvine, CA – November 14, 2019 – Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable rechargeable sacral neuromodulation

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2019 Axonics Modulation Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38721 45-4744083 (State or other jurisdiction of incorporat

AXNX / Axonics Modulation Technologies, Inc. CORRESP - -

Axonics Modulation Technologies, Inc. 26 Technology Drive Irvine, CA 92618 November 14, 2019 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Chris Edwards Re: Axonics Modulation Technologies, Inc. Registration Statement on Form S-3 Filed on November 6, 2019 File No. 333-234546 Request for Acceleration Acceleration Re

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2019 Axonics Modulation Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38721 45-4744083 (State or other jurisdiction of incorporat

Form of Indenture

Exhibit 4.4 AXONICS MODULATION TECHNOLOGIES, INC. Issuer AND as Trustee INDENTURE Dated as of , 20 Debt Securities CROSS-REFERENCE TABLE(1) SECTION OF TRUST INDENTURE ACT OF 1939, AS AMENDED SECTION(S) OF INDENTURE 310(b) 7.8 311(a) 7.13 311(b) 7.13 312(a) 5.2(a) 312(b) 5.2(b) 312(c) 5.2(c) 313(a) 5.4(a) 313(b) 5.4(b) 313(c) 5.4(b) (1) This Cross-Reference Table does not constitute part of the Ind

AXNX / Axonics Modulation Technologies, Inc. S-3 - - S-3

As filed with the Securities and Exchange Commission on November 6, 2019. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Axonics Modulation Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 45-4744083 (State or other jurisdiction of incorporation or organ

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2019 Axonics Modulation Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38721 45-4744083 (State or other jurisdiction of incorporati

Axonics® Responds to Patent Action by Medtronic Believes Claims are Without Merit and an Attempt to Suppress Innovation and Competition

Exhibit 99.1 Axonics® Responds to Patent Action by Medtronic Believes Claims are Without Merit and an Attempt to Suppress Innovation and Competition IRVINE, Calif. – November 5, 2019 – Axonics Modulation Technologies, Inc. (NASDAQ:AXNX), a medical technology company that has developed and is commercializing sacral neuromodulation (“SNM”) devices, today announced that it received notice on Monday,

Axonics® Announces U.S. Food & Drug Administration Approval for its Sacral Neuromodulation System Company to host conference call and webcast at 9:00 am EDT Today

Exhibit 99.1 Axonics® Announces U.S. Food & Drug Administration Approval for its Sacral Neuromodulation System Company to host conference call and webcast at 9:00 am EDT Today Irvine, CA – September 9, 2019 – Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing a novel implantable rechargeable sacral neuromodulation (“SNM”) de

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2019 Axonics Modulation Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38721 45-4744083 (State or other jurisdiction of incorporat

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2019 Axonics Modulation Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38721 45-4744083 (State or other jurisdiction of incorporatio

Axonics® Announces Second Quarter 2019 Financial Results and Operational Update

Exhibit 99.1 Axonics® Announces Second Quarter 2019 Financial Results and Operational Update IRVINE, CA – August 5, 2019 – Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing a novel implantable Sacral Neuromodulation (“SNM”) device for the treatment of urinary and bowel dysfunction, reported today financial results for the s

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2019 Axonics Modulation Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38721 45-4744083 (State or other jurisdiction of incorporation

AXNX / Axonics Modulation Technologies, Inc. 10-Q - Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38721 Axonics Mo

Executive Employment Agreement, dated June 5, 2019, by and between Raymond W. Cohen and the Registrant.

Exhibit 10.2 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (this “Agreement”) is dated as of June 5th, 2019 by and between Axonics Modulation Technologies, Inc., a Delaware corporation (the “Company”), and Raymond W. Cohen (“Executive”). WHEREAS, Executive currently serves as Chief Executive Officer and a director of the Company pursuant to an Executive Employment Agreement da

Executive Employment Agreement, dated June 5, 2019, by and between Dan L. Dearen and the Registrant.

Exhibit 10.3 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (this “Agreement”) is dated as of June 5, 2019 by and between Axonics Modulation Technologies, Inc., a Delaware corporation (the “Company”), and Dan L. Dearen (“Executive”). WHEREAS, Executive currently serves as Chief Operating and Financial Officer of the Company pursuant to an Executive Employment Agreement dated Ma

Executive Employment Agreement, dated June 5, 2019, by and between Rinda Sama and the Registrant.

Exhibit 10.4 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (this “Agreement”) is dated as of June 5, 2019 by and between Axonics Modulation Technologies, Inc., a Delaware corporation (the “Company”), and Rinda Sama (“Executive”). WHEREAS, Executive currently serves as Chief Operating Officer of the Company pursuant to an Executive Employment Agreement dated January 1, 2015, wi

Third Amendment to Lease, dated June 28, 2019, by and between The Irvine Company LLC and Axonics Modulation Technologies, Inc.

Exhibit 10.1 THIRD AMENDMENT TO LEASE I. PARTIES AND DATE. This Third Amendment to Lease (“Amendment”) dated June 28, 2019, is by and between THE IRVINE COMPANY LLC a Delaware limited liability company (“Landlord”), and AXONICS MODULATION TECHNOLOGIES, INC., a Delaware corporation (“Tenant”). II. RECITALS. On November 30, 2017, Landlord and Tenant entered into a lease, for space in a building loca

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2019 Axonics Modulation Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38721 45-4744083 (State or other jurisdiction of incorporation)

AXNX / Axonics Modulation Technologies, Inc. DEFA14A - - DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy State

Schedule 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Definitive Proxy State

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2019 Axonics Modulation Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38721 45-4744083 (State or other jurisdiction of incorporation)